Bottom line
Is ASD a good fund? The bottom line
ASD is an actively managed large blend ETF from Grayscale.
Its expense ratio is 0.79% — about $79 a year on every $10,000 invested, cheaper than 52% of large blend funds we track.
With $1.4 million in net assets and 39 holdings, its largest position is Definium Therapeutics Inc (4.8%) and the top 10 make up 30.8% of the portfolio.
What to watch
- Small fund ($1.4 million) — small funds are likelier to close
Updated Nov 19, 2026
What ASD invests in
The Defiance Autism Impact ETF (the Fund or the Autism ETF) seeks to track the total return performance, before fees and expenses, of the VettaFi Autism Impact Index (the Index).
The Fund uses a passive management (or indexing) approach to track the total return performance, before fees and expenses, of the Index. VettaFi Autism Impact Index The Index is designed to measure the performance of publicly traded global companies in developed markets that provide products, services and/or research supporting the autism ecosystem comprised of individuals on the autism spectrum and within the broader neurodivergent community (Autism Impact Companies). The Index seeks to provide diversified exposure to Autism Impact Companies operating across healthcare, pharmaceuticals, biotechnology, behavioral services, diagnostics, specialized education, and assistive technologies that address autism spectrum disorder (ASD) and related neurodevelopmental conditions. VettaFi LLC (VettaFi or the Index Provider), the index provider, selects and maintains the eligible Index universe.…
From the fund's prospectus (filed May 28, 2026).
What ASD costs
On a $10,000 investment, ASD's 0.79% expense ratio costs about $79 a year. The median large blend fund charges 0.83%.
ASD top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Definium Therapeutics Inc DFTX | 4.77% |
| 2 | Neuren Pharmaceuticals Ltd NEU | 3.23% |
| 3 | LifeStance Health Group Inc LFST | 3.04% |
| 4 | Otsuka Holdings Co Ltd 4578 | 2.95% |
| 5 | Acadia Healthcare Co Inc ACHC | 2.90% |
| 6 | ACADIA Pharmaceuticals Inc ACAD | 2.89% |
| 7 | MapLight Therapeutics Inc MPLT | 2.89% |
| 8 | AbbVie Inc ABBV | 2.72% |
| 9 | BrightSpring Health Services I BTSG | 2.70% |
| 10 | Revvity Inc RVTY | 2.68% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 30.8% of the fund. See all top 25 holdings and asset mix →